Cargando…

Progress in Prophylactic and Therapeutic EBV Vaccine Development Based on Molecular Characteristics of EBV Target Antigens

Epstein–Barr virus (EBV) was discovered in 1964 in the cell line of Burkitt lymphoma and became first known human oncogenic virus. EBV belongs to the Herpesviridae family, and is present worldwide as it infects 95% of people. Infection with EBV usually happens during childhood when it remains asympt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rozman, Marija, Korać, Petra, Jambrosic, Karlo, Židovec Lepej, Snjezana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414479/ https://www.ncbi.nlm.nih.gov/pubmed/36014985 http://dx.doi.org/10.3390/pathogens11080864

Ejemplares similares

miRNAs: EBV Mechanism for Escaping Host’s Immune Response and Supporting Tumorigenesis
por: Židovec Lepej, Snježana, et al.
Publicado: (2020)

Role of TLRs in HIV-1 Infection and Potential of TLR Agonists in HIV-1 Vaccine Development and Treatment Strategies
por: Rozman, Marija, et al.
Publicado: (2023)

Molecular Characterisation of Epstein–Barr Virus in Classical Hodgkin Lymphoma
por: Begić, Valerija, et al.
Publicado: (2022)

Prophylactic and Therapeutic EBV Vaccines: Major Scientific Obstacles, Historical Progress, and Future Direction
por: Cai, Jing, et al.
Publicado: (2021)

Progress in EBV Vaccines
por: van Zyl, Dwain G., et al.
Publicado: (2019)

Mendelian randomisation identifies priority groups for prophylactic EBV vaccination
por: Muckian, Marisa D., et al.
Publicado: (2023)

Distinct Expression Patterns of Genes Coding for Biological Response Modifiers Involved in Inflammatory Responses and Development of Fibrosis in Chronic Hepatitis C: Upregulation of SMAD-6 and MMP-8 and Downregulation of CAV-1, CTGF, CEBPB, PLG, TIMP-3, MMP-1, ITGA-1, ITGA-2 and LOX
por: Radmanić, Leona, et al.
Publicado: (2022)

A Glimpse on the Evolution of RNA Viruses: Implications and Lessons from SARS-CoV-2
por: Šimičić, Petra, et al.
Publicado: (2022)

Development of an Improved Epstein-Barr Virus (EBV) Neutralizing Antibody Assay to Facilitate Development of a Prophylactic gp350-Subunit EBV Vaccine
por: Liu, Hui, et al.
Publicado: (2020)

Four Decades of Prophylactic EBV Vaccine Research: A Systematic Review and Historical Perspective
por: Escalante, Gabriela M., et al.
Publicado: (2022)

Distribution of Epstein–Barr Virus LMP1 Variants in Patients with Infectious Mononucleosis and Association with Selected Biochemical and Hematological Parameters
por: Zidovec-Lepej, Snjezana, et al.
Publicado: (2023)

Infection with human cytomegalovirus, Epstein-Barr virus, and high-risk types 16 and 18 of human papillomavirus in EGFR-mutated lung adenocarcinoma
por: Harabajsa, Suzana, et al.
Publicado: (2023)

The Characteristics of Epstein‐Barr Virus (EBV)‐positive Diffuse Large B‐Cell Lymphoma: Comparison between EBV(+) and EBV(‐) Cases in Japanese Population
por: Kuze, Tetuo, et al.
Publicado: (2000)

Molecular Epidemiology and Baseline Resistance of Hepatitis C Virus to Direct Acting Antivirals in Croatia
por: Simicic, Petra, et al.
Publicado: (2022)

EBV & lymphoma
por: Caballero, Dolores
Publicado: (2019)

EBV and Lymphomagenesis
por: Sausen, Daniel G., et al.
Publicado: (2023)

The Role of NK Cells in EBV Infection and EBV-Associated NPC
por: Png, Yi Tian, et al.
Publicado: (2021)

EBV-induced T-cell responses in EBV-specific and nonspecific cancers
por: Zhang, Qiuting, et al.
Publicado: (2023)

Molecular mechanisms of EBV-driven cell cycle progression and oncogenesis
por: Yin, Huali, et al.
Publicado: (2018)

The Role of Stem Cell Factor, Epidermal Growth Factor and Angiopoietin-2 in HBV, HCV, HCC and NAFLD
por: Radmanić, Leona, et al.
Publicado: (2022)

The EBV Gastric Cancer Resource (EBV-GCR): A Suite of Tools for Investigating EBV-Associated Human Gastric Carcinogenesis
por: Salnikov, Mikhail Y., et al.
Publicado: (2023)

GMP development and preclinical validation of CAR-T cells targeting a lytic EBV antigen for therapy of EBV-associated malignancies
por: Zhang, Xi, et al.
Publicado: (2023)

Curcuminoids as EBV Lytic Activators for Adjuvant Treatment in EBV-Positive Carcinomas
por: Ramayanti, Octavia, et al.
Publicado: (2018)

The role of EBV-encoded miRNA in EBV-associated gastric cancer
por: Liu, Ting, et al.
Publicado: (2023)

EBV Positive Gastric Carcinomas and Their Clinicopathological Characteristics
por: Ognjenovic, Ljubomir, et al.
Publicado: (2018)

Distinct Cytokine Profiles in Severe COVID-19 and Non-Alcoholic Fatty Liver Disease
por: Papic, Neven, et al.
Publicado: (2022)

Molecular Properties and Therapeutic Targeting of the EBV-Encoded Receptor BILF1
por: Knerr, Julius Maximilian, et al.
Publicado: (2021)

EBV in Hodgkin Lymphoma
por: Massini, Giuseppina, et al.
Publicado: (2009)

EBV Chronic Infections
por: Eligio, Pizzigallo, et al.
Publicado: (2010)

EBV and human cancer
por: Ko, Young-Hyeh
Publicado: (2015)

Antiviral Drugs for EBV
por: Pagano, Joseph S., et al.
Publicado: (2018)

The Potential for EBV Vaccines to Prevent Multiple Sclerosis
por: Maple, Peter A., et al.
Publicado: (2022)

The impact of HLA class I and EBV latency‐II antigen‐specific CD8(+) T cells on the pathogenesis of EBV(+) Hodgkin lymphoma
por: Jones, K., et al.
Publicado: (2015)

From Anti-EBV Immune Responses to the EBV Diseasome via Cross-reactivity
por: Kanduc, Darja, et al.
Publicado: (2020)

Plasma EBV DNA as a prognostic factor in EBV associated gastric cancer: a multicenter, prospective study (EBV PRESAGE study)
por: Alberti, Andrea, et al.
Publicado: (2023)

Declining Epstein-Barr Virus Antibody Prevalence in College Freshmen Strengthens the Rationale for a Prophylactic EBV Vaccine
por: Balfour, Henry H., et al.
Publicado: (2022)

Tumor Molecular and Microenvironment Characteristics in EBV-Associated Malignancies as Potential Therapeutic Targets: Focus on Gastric Cancer
por: Atri-Schuller, Aviva, et al.
Publicado: (2022)

Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies
Publicado: (1992)

Generating CTLs against the subdominant EBV LMP antigens by transit expression of an A20 inhibitor with EBV LMP proteins in human DCs
por: Hong, Bangxing, et al.
Publicado: (2011)

Establishment of Epstein–Barr Virus (EBV) Latent Gene-Expressing T-Cell Lines with an Expression Vector Harboring EBV Nuclear Antigen 1
por: Kanno, Hiroyuki, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4lq40ojkg8tb56urilnfh4iflc